Delirium following pregabalin discontinuation in an individual with no psychiatric or substance use history.


Journal

BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291

Informations de publication

Date de publication:
17 Nov 2023
Historique:
medline: 20 11 2023
pubmed: 18 11 2023
entrez: 17 11 2023
Statut: epublish

Résumé

We report about a man in his mid-50s who was prescribed pregabalin (150 mg/day) for neuropathic pain due to a herniated intervertebral disc. Four weeks later, he presented to the emergency room with symptoms consistent with delirium. After ruling out acute intoxication with a substance and neurological causes, collateral information from the family and review of his medical chart indicated potential discontinuation syndrome owing to pregabalin. Following the successful treatment and resolution of delirium, the patient revealed he had been consistently consuming pregabalin doses upwards of 2 g/day over the past 2 weeks, leading to the premature exhaustion of his prescription and an abrupt cessation. The case findings underscore the necessity for physicians to recognise the potential for pregabalin misuse and the associated withdrawal risks, including delirium.

Identifiants

pubmed: 37977830
pii: 16/11/e258104
doi: 10.1136/bcr-2023-258104
pmc: PMC10660150
pii:
doi:

Substances chimiques

Pregabalin 55JG375S6M

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© BMJ Publishing Group Limited 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Br J Clin Pharmacol. 2022 Aug;88(8):3911-3917
pubmed: 35435281
J Opioid Manag. 2015 Jan-Feb;11(1):27-35
pubmed: 25750162
Clin Neuropharmacol. 2009 Jul-Aug;32(4):236-7
pubmed: 19644235
JAMA. 2018 Nov 27;320(20):2149-2151
pubmed: 30480717
Alpha Psychiatry. 2021 Mar 18;22(2):118-119
pubmed: 36425938
Adv Clin Chem. 2022;111:217-263
pubmed: 36427911
Gen Hosp Psychiatry. 2012 Jul-Aug;34(4):436.e1-2
pubmed: 22177026
CNS Drugs. 2016 Jan;30(1):9-25
pubmed: 26767525
JAMA Intern Med. 2019 May 1;179(5):695-701
pubmed: 30907944
Drugs. 2017 Mar;77(4):403-426
pubmed: 28144823
Nat Rev Drug Discov. 2005 Jun;4(6):455-6
pubmed: 15959952
J Surg Case Rep. 2023 Jun 27;2023(6):rjad375
pubmed: 37388509
Can J Neurol Sci. 2013 Jan;40(1):126-7
pubmed: 23427359
PLoS Med. 2017 Oct 3;14(10):e1002396
pubmed: 28972983
Eur Neuropsychopharmacol. 2017 Dec;27(12):1185-1215
pubmed: 28988943
Arq Neuropsiquiatr. 2012 Dec;70(12):960-1
pubmed: 23295427
Subst Abuse. 2018 Sep 23;12:1178221818801311
pubmed: 30262984
Br J Pain. 2020 May;14(2):104-114
pubmed: 32537149
Psychiatr Serv. 2021 Nov 1;72(11):1246-1253
pubmed: 34015964

Auteurs

Harshal Awasthi (H)

Addiction Psychiatry, Matra Chhaya Medical Centre, Kanpur, Uttar Pradesh, India dr.harshal.awasthi@gmail.com.
Interior Health Authority - East Kootenay, Cranbrook, British Columbia, Canada.

Abhimanyu Vohra (A)

Addiction Medicine, Matra Chhaya Medical Centre, Kanpur, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH